艾滋病治疗新药绥美凯效果如何？

(Dolutegravir, abacavir and lamivudine) is a new fixed-dose compound preparation against human immunodeficiency virus (HIV) infection that contains three ingredients: dolutegravir, abacavir and lamivudine. It is suitable for the treatment of HIV infection in adults and adolescents aged 12 years and above. Current HIV drugs have shortcomings such as a high incidence of adverse reactions, poor tolerance, and many drug interactions, and there is a possibility of drug resistance after long-term medication. This drug has certain clinical advantages over already marketed treatment options and adds new treatment options to the clinic. So, what is the effect of the new AIDS treatment drug Suimeikai?

Suimeike (dolutegravir tablets) is currently the only three-in-one compound drug containing dolutegravir (DrG), which integrates treatment drugs for different stages of viral infection into the same tablet. Patients only need to take one drug to achieve the effect of combined medication. The drug has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. Comparing it with the other two integrase inhibitor first-line regimens of RAL (Ascent) and EVG (elvitegravir) in patients who failed treatment, Suimeike (Dolutea Balamib Tablets) has significantly fewer drug-resistant mutation sites than the other two drugs, making it less likely to develop drug resistance.

(Dolutea Paramid Tablets) has been approved for marketing in many countries, and has been recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for first-time AIDS patients. It can also become a treatment option for domestic AIDS patients.

Recommended hot articles: /newsDetail/83763.html